PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces SensoLyte® Factor Xa Activity Assays - Industry’s First Fluorimetric Kits - AnaSpec, EGT Group is pleased to announce the release of the industry first fluorimetric Factor Xa activity assays - The SensoLyte® 520 Factor Xa Assay Kit and the SensoLyte® Rh110 Factor Xa Assay Kit - Anaspec.com / Eurogentec.com
AnaSpec Introduces SensoLyte® Factor Xa Activity Assays - Industry’s First Fluorimetric Kits

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2012/01/30 - AnaSpec, EGT Group is pleased to announce the release of the industry first fluorimetric Factor Xa activity assays - The SensoLyte® 520 Factor Xa Assay Kit and the SensoLyte® Rh110 Factor Xa Assay Kit - Anaspec.com / Eurogentec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The SensoLyte® 520 Factor Xa Assay Kit employs a FRET (5-FAM/QXL™ 520) substrate and the SensoLyte® Rh110 Factor Xa Assay Kit, a substrate labeled with the fluorophore, Rh110. Both substrates are fluorescent substrates emitting in the green range of 520 nm, with excitation at 490 nm. The longer-wavelength spectra of 5-FAM and Rhodamine 110 provide greater sensitivity and less interference from other reaction components, making these kits ultra-sensitive. The detection limit of the SensoLyte® 520 kit can reach as low as 7.8 ng/mL while the SensoLyte® Rho110 reaches as low as 0.31 ng/mL.

Key highlights for AnaSpec’s new SensoLyte® Factor Xa Assay Kits:

• Kits optimized to detect Factor Xa enzyme activity
• Fluorometric, long wavelength (Ex/Em=490/520 nm) read-out assays
• Minimal autofluorescence
• Kits provide ample reagents to perform 100 assays in a 96-well plate format
• Assays can be completed in one hour.
Factor Xa (FXa) is a serine endopeptidase composed of two disulfide-linked subunits. FXa leads to blood clot formation by converting prothrombin to thrombin through the prothrombinase complex. FXa is generated from zymogen Factor X via the intrinsic and extrinsic pathways and is the rate-limiting step in the propagation of thrombin generation. In the presence of Ca2+ ions, FXa forms prothrombinase with factor Va on the phospholipid membrane of the activated platelets.1-3 FXa has emerged as an attractive target for drug discovery for thromboembolic diseases.4,5

Reference
1. Furie, B. and Furie, BC. Cell 53:505–518 (1988).
2. Davie, EW. et al. Biochemistry 30:10363–10370(1991).
3. Mann, KG. Thromb Haemost 82:165-174 (1999).
4. Camm, AJ. and Bounameaux, H. Drugs 71:1503-1526 (2011).
5. Weitz, JI. Thromb Res 127 Suppl 2:S5-S12 (2011).

For more information, please visit anaspec.com or eurogentec.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces SensoLyte® Factor Xa Activity Assays - Industry’s First Fluorimetric Kits

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)